Machelle Sanders

Track

Insider profile

Currently holds a position at Novan Inc

Performance

Overall performance
2.2
Performance over holding periods
2.2
30 days 90 days 120 days
Average return -5% 8.2% 15.1%
Success rate 53% 68% 82%
Transactions
2 0% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Director Novan Inc Sept. 24, 2017 -
Machelle Sanders's trades of BioCryst Pharmaceuticals Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-11-17 2025-11-13
PlS Planned sale
60,921 +9.7%
199.79
US$551,079 		60,921 +9.7% 199.79 US$551,079
2025-11-13 2025-11-13
PrS Proposed sale
83,325
363.70
US$4,468,421 		83,325 363.70 US$4,468,421
2024-06-17 2024-06-17
PrS Proposed sale
30,342
123.21
US$333,999 		30,342 123.21 US$333,999
2024-06-17 2024-06-17
S Sale
4,689 -14.5%
6.00
US$28,134 		4,689 -14.5% 6.00 US$28,134
2023-06-27 2023-06-27
US Novan Inc (NOVN)
S Sale
11,553 -31.4%
0.41
US$4,716 		11,553 -31.4% 0.41 US$4,716
2023-06-15 2023-06-15
PrS Proposed sale
4,000
7.94
US$31,779 		4,000 7.94 US$31,779
2023-06-15 2023-06-15
S Sale
4,000 -13.5%
7.98
US$31,920 		4,000 -13.5% 7.98 US$31,920
2020-03-05 2020-03-03
US Novan Inc (NOVN)
B Purchase
7,000
0.00
US$0 		7,000 0.00 US$0